This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Bilberry
DrugBank Accession Number
DB14235
Background

Not Available

Type
Biotech
Groups
Approved, Experimental
Synonyms
  • Bilberry fruit
  • Dried billberry fruit (vaccinium myrtillus l.)
  • Dwarf bilberry
  • Dwarf bilberry fruit
  • European blueberry
  • European blueberry fruit
  • Fresh billberry fruit (vaccinium myrtillus l.)
  • Myrtilli fructus
  • Myrtilli fructus recens (vaccinium myrtillus l.)
  • Myrtilli fructus siccus (vaccinium myrtillus l.)
  • Myrtillus
  • Myrtle blueberry
  • Myrtle blueberry fruit
  • Myrtle whortleberry
  • Myrtle whortleberry fruit
  • Vaccinium myrtillus
  • Vaccinium myrtillus dry fruit
  • Vaccinium myrtillus fruit
  • Whortleberry
External IDs
  • B1064
  • B2013

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Associated Conditions
Associated Therapies
Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug events
Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
No interactions found.

Products

Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
Over the Counter Products
NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage
Bilberry Extract TabletsTablet7500 mg / tabOralAbundance Naturally LtdNot applicableNot applicableCanada flag
Unapproved/Other Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing EndRegionImage
Prenate ChewableBilberry (25 mg/1) + Biotin (280 ug/1) + Boron (250 ug/1) + Calcium carbonate (500 mg/1) + Cholecalciferol (300 [iU]/1) + Cyanocobalamin (125 mg/1) + Folic acid (1 mg/1) + Magnesium oxide (50 mg/1) + Pyridoxine hydrochloride (10 mg/1)Tablet, chewableOralAvion Pharmaceuticals, Llc2013-01-16Not applicableUS flag
VP-PrecipBilberry (40 mg/1) + Evening primrose oil (500 mg/1) + Linseed oil (1000 mg/1)Capsule, gelatin coatedOralVirtus Pharmaceuticals2012-05-182016-03-03US flag

Categories

Drug Categories
Classification
Not classified
Affected organisms
Not Available

Chemical Identifiers

UNII
9P2U39H18W
CAS number
Not Available

References

General References
Not Available
RxNav
125929
Wikipedia
Bilberry

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2WithdrawnSupportive CareMucositis / Recurrent Squamous Cell Carcinoma of the Hypopharynx / Recurrent Squamous Cell Carcinoma of the Larynx / Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity / Recurrent Squamous Cell Carcinoma of the Nasopharynx / Recurrent Squamous Cell Carcinoma of the Oropharynx / Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity / Recurrent Verrucous Carcinoma of the Larynx / Recurrent Verrucous Carcinoma of the Oral Cavity / Stage III Squamous Cell Carcinoma of the Hypopharynx / Stage III Squamous Cell Carcinoma of the Larynx / Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity / Stage III Squamous Cell Carcinoma of the Nasopharynx / Stage III Squamous Cell Carcinoma of the Oropharynx / Stage III Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity / Stage III Verrucous Carcinoma of the Larynx / Stage III Verrucous Carcinoma of the Oral Cavity / Stage IV Squamous Cell Carcinoma of the Hypopharynx / Stage IV Squamous Cell Carcinoma of the Nasopharynx / Stage IVA Squamous Cell Carcinoma of the Larynx / Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity / Stage IVA Squamous Cell Carcinoma of the Oropharynx / Stage IVA Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity / Stage IVA Verrucous Carcinoma of the Larynx / Stage IVA Verrucous Carcinoma of the Oral Cavity / Stage IVB Squamous Cell Carcinoma of the Larynx / Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity / Stage IVB Squamous Cell Carcinoma of the Oropharynx / Stage IVB Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity / Stage IVB Verrucous Carcinoma of the Larynx / Stage IVB Verrucous Carcinoma of the Oral Cavity / Tongue Cancers1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
TabletOral7500 mg / tab
CapsuleOral
Tablet, chewableOral
CapsuleOral
Granule, for solutionOral
TabletOral
Capsule, gelatin coatedOral
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Drug created at July 05, 2018 02:49 / Updated at September 20, 2022 00:05